Conditions

When glucose numbers improve, patients are expected to feel better. Yet some people with type 1 diabetes report the opposite. A glucose level that looks reassuring on a continuous glucose monitor may leave them feeling tired, uncomfortable, or simply “off.” New research suggests that glycemic habituation may help explain this …

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

Could a routine blood sample someday reveal cardiovascular danger that cholesterol, blood pressure, and HbA1c do not fully capture? New research suggests that epigenetic cardiovascular risk prediction could offer a new way to identify people with type 2 diabetes who face a higher short-term risk of major cardiovascular events. Instead …

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes, but their effects on gastrointestinal motility remain an important clinical consideration. Opioids can also slow gastrointestinal function, raising an obvious question: what happens when patients need both? New research examining GLP-1 and opioid interactions suggests that opioid choice may …

Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use …

Three decades of advances in diabetes care have transformed how people with type 1 diabetes manage glucose. Insulin pumps, continuous glucose monitoring (CGM), improved insulin analogs, automated insulin delivery, and earlier screening have all changed daily treatment. However, have these advances actually reduced the long-term complications of type 1 diabetes? …

A1C is one of the most useful tools in diabetes care, but it has an important limitation: it takes time to reflect change. Could a faster-moving marker help clinicians know sooner whether treatment is working? New randomized research on glycated albumin in diabetes offers an intriguing answer. Glycated albumin reflects …

A diabetes app can track meals, count steps, log glucose, and deliver reminders. However, can an app actually help someone turn all that information into lasting daily habits? A recent randomized controlled trial suggests that digital diabetes coaching, with technology supported by ongoing human guidance, may help bridge that gap. …

Does eating more fat automatically mean that more harmful fatty acids will circulate in the blood? A new randomized trial suggests the answer may be more complicated. Researchers studying a low-carb diet for type 2 diabetes found that six months of carbohydrate restriction changed circulating fatty acids in potentially favorable …

Medical nutrition therapy for diabetes is often discussed in terms of A1C, glucose levels, and weight. However, could personalized nutrition also influence inflammation and other aspects of metabolic health? A recent randomized controlled trial offers an intriguing reason to ask that question. Researchers found that individualized medical nutrition therapy with …